Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
A Randomized, Double-Blind, Placebo-controlled Multicenter Study to Assess the Efficacy and Safety of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
- Major Depressive Disorder
At a glance
- Phase
- Phase 3
- Study type
- Interventional
- Sponsor
- Intra-Cellular Therapies, Inc.
- Enrolment target
- 470
- Started
- 2 May 2023
- Main results due (estimated)
- 5 April 2027
- Study ends (estimated)
- 5 April 2027
- Allocation
- Randomized
- Design
- Parallel
- Purpose
- Treatment
- Masking
- Triple (participant, investigator, outcomes assessor)
- Sites
- 69 · 13 in India
- First posted
- 9 May 2023
- Registry updated
- 3 November 2026
Can you take part?
- Ages 18 years to 65 years.
- Open to any sex.
- You need the condition being studied. Healthy volunteers are not accepted.
Age groups: adult, older adult.
These are the headline rules. Every study has a longer list, and whether you are eligible is decided by the research team at the site, never by this page.
Read the full eligibility criteria
Inclusion Criteria: 1. Male or female patients between the ages of 18 and 65 years, inclusive; 2. Meets DSM-5 criteria for MDD (MDD with psychotic features will be acceptable) as confirmed by the Investigator or Sponsor-approved rater using the modified Structured Clinical Interview for DSM-5, Clinical Trials Version (SCID-5-CT) and meets all of the following criteria: 1. The start of the current major depressive episode (MDE) is at least 12 weeks but not more than 18 months prior to Screening; 2. Has at least moderate severity of illness based on rater-administered MADRS total score ≥ 24 at Screening and at Baseline; 3. Has at least moderate severity of illness based on CGI-S score ≥ 4 at Screening and at Baseline; 4. Has a Quick Inventory of Depressive Symptomatology-Self Report-16 item (QIDS-SR-16) score ≥ 14 at Screening and at Baseline; 5. Has sufficient history and medical record confirmation verifying the ADT and the current MDE is causing clinically significant distress or impairment in social, occupational, or other important areas of functioning. 3. Currently having an inadequate response (less than 50% improvement) to 2 or more ADTs in the current MDE as confirmed by the Investigator using the Antidepressant Treatment Response Questionnaire (ATRQ) and taking at least the minimum effective dose (per package insert) of one of the following antidepressants as monotherapy treatment for at least 6 weeks duration: 1. citalopram/escitalopram 2. fluoxetine 3. paroxetine 4. sertraline 5. duloxetine 6. levomilnacipran/milnacipran (if locally approved for MDD) 7. venlafaxine/desvenlafaxine 8. bupropion 9. vilazodone 10. vortioxetine Exclusion Criteria: 1. Within the patient's lifetime, has a confirmed DSM-5 psychiatric diagnosis other than MDD, including: 1. Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder or other psychotic disorder; 2. Bipolar Disorder; 2. Within 6 months of Screening, has a confirmed DSM-5 psychiatric diagnosis other than MDD including: 1. Anxiety disorders such as Panic Disorder or Generalized Anxiety Disorder; Obsessive-compulsive Disorder; Posttraumatic Stress Disorder as primary diagnoses. Note: Anxiety symptoms may be allowed if secondary to MDD, provided these symptoms do not require concurrent treatment; 2. Eating disorder; 3. Substance use disorders (excluding nicotine); 4. Personality disorder of sufficient severity to have a major impact on the patient's psychiatric status; 5. Within 12 months of Screening, has had any other psychiatric condition (other than MDD) that has been the main focus of treatment; 3. The patient experiences a ≥ 25% decrease in the MADRS total score between Screening and Baseline; 4. The patient experiences a ≥ 25% decrease in the QIDS-SR-16 total score between Screening and Baseline; 5. In the opinion of the Investigator, the patient has a significant risk for suicidal behavior during participation in the study or: 1. At Screening, the patient scores "yes" on Suicidal Ideation Items 4 or 5 of the Columbia-Suicide Severity Rating Scale (C-SSRS) within 6 months prior to Screening, or at Baseline, the patient scores "yes" on Suicidal Ideation Items 4 or 5 since the Screening Visit; 2. At Screening, the patient has had 1 or more suicide attempts within 2 years prior to Screening; 3. At Screening or Baseline, the patient scores ≥ 5 on MADRS Item 10 (Suicidal Thoughts), or 4. The patient is considered to be in imminent danger to him/herself or others. 6. The patient has a first MDE at age 60 years or older.
What this study is about
In the sponsor’s own words, from the registry.
This is a multicenter, randomized, double-blind, placebo-controlled parallel-group, fixed-dose study in patients with a primary diagnosis of MDD according to criteria of the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) who have an inadequate response to ongoing ADT.
Read the detailed description
The study will be conducted in three periods:
* Screening Period (up to 2 weeks) during which patient eligibility will be assessed. * Double-blind Treatment Period (6 weeks) in which all patients will be randomized to receive placebo or lumateperone 42 mg/day in 1:1 ratio. * Safety Follow-up Period (1 week) in which all patients will return to the clinic for a safety follow-up visit approximately one week after the last dose of study treatment.
Keywords: Adjunctive MDD Therapy
What participants receive
- Experimental
Lumateperone 42 mg
Drug: Lumateperone
- Placebo comparator
Placebo
Drug: Placebo
Interventions
LumateperoneDrug
Lumateperone 42 mg capsules administered orally, once daily
PlaceboDrug
Matching capsules administered orally, once daily
What the study measures
Primary outcomes
Montgomery-Asberg Depression Rating Scale
The MADRS is a clinician-rated 10 item scale to assess depressive symptoms. Each item is rated on a 7-point scale from 0-6. The total score ranges from 0 to 60 with a higher score indicating increased severity of depressive symptoms.
Time frame: Day 43
Secondary outcomes
Clinical Global Impression Scale-Severity
The CGI-S is a clinician-rated scale to assess a patient's overall mental health. The scale ranges from 1 (normal, not at all ill) to 7 (among the most extremely ill patients).
Time frame: Day 43
Who is running it
- Lead sponsor
- Intra-Cellular Therapies, Inc.
- Sponsor type
- Industry
- Responsible party
- The sponsor
- Organisation
- Intra-Cellular Therapies, Inc.
- Data monitoring committee
- No
- US FDA-regulated drug
- Yes
- US FDA-regulated device
- No
- Sponsor's study ID
- ITI-007-505
- Other IDs
- ITI-007-505
Intra-Cellular Therapies, Inc. Clinical Trial
Study director
Intra-Cellular Therapies, Inc.
Study sites(69)
Baramati Hospital
Bārāmati, India
Recruiting
S P Medical College And Associated Group of Hospitals
Bikaner, India
Recruiting
Post Graduate Institute of Medical Education And Research PGIMER
Chandigarh, India
Recruiting
Swastik Hospital
Kolhāpur, India
Recruiting
KIMS-Kingsway Hospitals
Nagpur, India
Recruiting
Divyam Hospital
Palsāna, India
Recruiting
Shree Samarth Hospital
Pune, India
Recruiting
Ratandeep Surgical Hospital And Endoscopy Clinic
Ahmedabad, India
Suspended
Sushrusha Navneet Memorial Hospital
Ahmedabad, India
Suspended
J L N Medical College and Attached Hospitals
Ajmer, India
Suspended
Gauhati Medical College and Hospital
Guwahati, India
Completed
Nagecha Hospital
Rajkot, India
Completed
Acharya vinoba bhave rural hospital
Wardha, India
Suspended
University of Alabama at Birmingham
Huntsville, Alabama, United States
Recruiting
CNRI-Los Angeles, LLC
Pico Rivera, California, United States
Recruiting
University of Connecticut Health Center
Farmington, Connecticut, United States
Recruiting
Premier Clinical Research Institute
Miami, Florida, United States
Recruiting
Miami Jewish Health System
Miami, Florida, United States
Recruiting
Interventional Psychiatry of Tampa Bay
Tampa, Florida, United States
Recruiting
The Emory Clinic
Atlanta, Georgia, United States
Recruiting
CenExeli Research LLC
Decatur, Georgia, United States
Recruiting
Collective Medical Research
Overland Park, Kansas, United States
Recruiting
Psychiatric Care and Research Center (PCRC)
O'Fallon, Missouri, United States
Recruiting
Bio Behavioral Health
Toms River, New Jersey, United States
Recruiting
SPRI Clinical Trials, LLC
Brooklyn, New York, United States
Recruiting
Manhattan Behavioral Medicine
New York, New York, United States
Recruiting
Quest Therapeutics of Avon Lake
Avon Lake, Ohio, United States
Recruiting
University of Cincinnati Medical Center
Cincinnati, Ohio, United States
Recruiting
The Ohio State University
Columbus, Ohio, United States
Recruiting
University of Pennsylvania - Perelman School of Medicine
Philadelphia, Pennsylvania, United States
Recruiting
DM Clinical Research
Houston, Texas, United States
Recruiting
Pillar Clinical Research, LLC
Richardson, Texas, United States
Recruiting
Northwest Clinical Research Center
Bellevue, Washington, United States
Recruiting
Ambulatory for Individual Practice for Specialized Medical Care in Psychiatry Dr. Ivo Natsov ET
Cherven Bryag, Bulgaria
Recruiting
Medical Center Lifemed
Kardzhali, Bulgaria
Recruiting
Medical Center Medconsult-Pleven
Pleven, Bulgaria
Recruiting
Medical Center Mentalcare OOD
Plovdiv, Bulgaria
Recruiting
MHC - Sofia, EOOD
Sofia, Bulgaria
Recruiting
Medical Center Hera EOOD
Sofia, Bulgaria
Recruiting
Medical Center Intermedica, OOD
Sofia, Bulgaria
Recruiting
Showing 40 of 69 sites. 53 recruiting, 12 not recruiting and 4 cancelled; 13 in India. Not recruiting covers sites not yet open, finished enrolling, completed or paused; cancelled covers sites withdrawn before opening or stopped for good.
References and data sharing
- Participant data shared
- No
Source: ClinicalTrials.gov record NCT05850689, status verified November 2026. Trialion does not run this study, is not paid to refer anyone to it, and cannot enrol you. Eligibility is always decided by the research team at the site.
Interested in this study?
Tell us how to reach you and we will connect you with the study team. Or refer someone you care for, with their permission.